Bulletin
Investor Alert

New York Markets Open in:

Market Pulse Archives

June 20, 2019, 8:27 a.m. EDT

Edesa Biotech stock rockets 140% after FDA gives go-ahead to early-stage trial

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Edesa Biotech Inc. (EDSA)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Sarah Toy

Shares of Edesa Biotech Inc. /zigman2/quotes/200172674/composite EDSA -2.02% shot up 140% in premarket trade after the Toronto-based company said the FDA had given it the go-ahead to start a Phase 2b trial looking at a topical treatment for chronic allergic contact dermatitis. The treatment, called EB01, is the company's lead drug candidate. "There are limited options for ACD patients and we have been pleased with the level of interest from physicians in the U.S.," said Par Nijhawan, Edesa's chief executive officer. "The company is committed to rapidly advancing our clinical plans and remains on track to initiate our clinical study for EB01." Shares of Edesa have declined 22.5% in the year to date through Wednesday, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.90% has gained 16.7%.

/zigman2/quotes/200172674/composite
US : U.S.: Nasdaq
$ 6.32
-0.13 -2.02%
Volume: 126,846
Nov. 30, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$85.76 million
Rev. per Employee
$27,400
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,567.00
-88.27 -1.90%
Volume: 4.07B
Nov. 30, 2021 4:57p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.